Cross-sectional Study of Bone Density, Bone Microarchitecture, Vertebral Fractures and Trabecular Bone Score in Patients With Acromegaly Treated With Pegvisomant Compared to Patients With Untreated Active Acromegaly
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- 12 Jul 2021 Status changed from recruiting to completed.
- 16 Feb 2019 Planned End Date changed from 30 Dec 2018 to 1 Mar 2020.
- 16 Feb 2019 Planned primary completion date changed from 30 Dec 2018 to 1 Mar 2020.